- Home
- EDTK vs GOVX Comparison
EDTK vs GOVX Comparison
Compare EDTK & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDTK
- GOVX
- Stock Information
- Founded
- EDTK 2013
- GOVX 2001
- Country
- EDTK China
- GOVX United States
- Employees
- EDTK N/A
- GOVX N/A
- Industry
- EDTK Other Consumer Services
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- EDTK Real Estate
- GOVX Health Care
- Exchange
- EDTK Nasdaq
- GOVX Nasdaq
- Market Cap
- EDTK 16.7M
- GOVX 16.8M
- IPO Year
- EDTK 2020
- GOVX N/A
- Fundamental
- Price
- EDTK $1.06
- GOVX $0.57
- Analyst Decision
- EDTK
- GOVX Strong Buy
- Analyst Count
- EDTK 0
- GOVX 3
- Target Price
- EDTK N/A
- GOVX $10.67
- AVG Volume (30 Days)
- EDTK 5.3K
- GOVX 867.0K
- Earning Date
- EDTK 08-08-2025
- GOVX 11-07-2025
- Dividend Yield
- EDTK N/A
- GOVX N/A
- EPS Growth
- EDTK N/A
- GOVX N/A
- EPS
- EDTK N/A
- GOVX N/A
- Revenue
- EDTK $893,690.00
- GOVX $6,143,044.00
- Revenue This Year
- EDTK N/A
- GOVX N/A
- Revenue Next Year
- EDTK N/A
- GOVX N/A
- P/E Ratio
- EDTK N/A
- GOVX N/A
- Revenue Growth
- EDTK N/A
- GOVX 1943.07
- 52 Week Low
- EDTK $0.80
- GOVX $0.43
- 52 Week High
- EDTK $1.20
- GOVX $3.88
- Technical
- Relative Strength Index (RSI)
- EDTK 51.12
- GOVX 45.97
- Support Level
- EDTK $0.97
- GOVX $0.54
- Resistance Level
- EDTK $1.07
- GOVX $0.61
- Average True Range (ATR)
- EDTK 0.04
- GOVX 0.04
- MACD
- EDTK 0.00
- GOVX 0.00
- Stochastic Oscillator
- EDTK 61.59
- GOVX 36.52
About EDTK Skillful Craftsman Education Technology Limited
Skillful Craftsman Education Technology Ltd provides online education and technology services in China. The services comprises of two aspects - Online vocational training and Virtual simulation experimental training. It covers a wide range of subjects, including mechanics, electronics, auto repair and construction. Majority of its revenues are generated from the People's Republic of China.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.